Does combination pharmacological intervention for smoking cessation prevent post-cessation weight gain? A systemic review

Yang, Mo; Bhowmik, Debajyoti; Wang, Xin; Abughosh, Susan

doi:10.1016/j.addbeh.2012.11.007

Cited by 14 publications

(10 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data were considered strongly suggestive of a causal relationship by participants in the 2011 NTP workshop and are supported by findings from animal studies ( Behl et al 2013 ). The association with obesity or overweight following exposure during development is different from effects that occur with exposure later in life, where smoking is known to suppress appetite, and adult smokers tend to gain weight after smoking cessation ( Yang et al 2013 ; Zoli and Picciotto 2012 ). Rats exposed to nicotine during perinatal development tended to have higher body weight and more fat mass compared with controls; typically, the effect first became apparent at weaning and persisted through adulthood ( Behl et al 2013 ).…”

Section: Resultsmentioning

confidence: 96%

Prioritizing Environmental Chemicals for Obesity and Diabetes Outcomes Research: A Screening Approach Using ToxCast™ High-Throughput Data

Auerbach

Filer

Reif

et al. 2016

Environ Health Perspect

View full text Add to dashboard Cite

Background:Diabetes and obesity are major threats to public health in the United States and abroad. Understanding the role that chemicals in our environment play in the development of these conditions is an emerging issue in environmental health, although identifying and prioritizing chemicals for testing beyond those already implicated in the literature is challenging. This review is intended to help researchers generate hypotheses about chemicals that may contribute to diabetes and to obesity-related health outcomes by summarizing relevant findings from the U.S. Environmental Protection Agency (EPA) ToxCast™ high-throughput screening (HTS) program.Objectives:Our aim was to develop new hypotheses around environmental chemicals of potential interest for diabetes- or obesity-related outcomes using high-throughput screening data.Methods:We identified ToxCast™ assay targets relevant to several biological processes related to diabetes and obesity (insulin sensitivity in peripheral tissue, pancreatic islet and β cell function, adipocyte differentiation, and feeding behavior) and presented chemical screening data against those assay targets to identify chemicals of potential interest.Discussion:The results of this screening-level analysis suggest that the spectrum of environmental chemicals to consider in research related to diabetes and obesity is much broader than indicated by research papers and reviews published in the peer-reviewed literature. Testing hypotheses based on ToxCast™ data will also help assess the predictive utility of this HTS platform.Conclusions:More research is required to put these screening-level analyses into context, but the information presented in this review should facilitate the development of new hypotheses.Citation:Auerbach S, Filer D, Reif D, Walker V, Holloway AC, Schlezinger J, Srinivasan S, Svoboda D, Judson R, Bucher JR, Thayer KA. 2016. Prioritizing environmental chemicals for obesity and diabetes outcomes research: a screening approach using ToxCast™ high-throughput data. Environ Health Perspect 124:1141–1154; http://dx.doi.org/10.1289/ehp.1510456

show abstract

Section: Resultsmentioning

confidence: 96%

Prioritizing Environmental Chemicals for Obesity and Diabetes Outcomes Research: A Screening Approach Using ToxCast™ High-Throughput Data

Auerbach

Filer

Reif

et al. 2016

Environ Health Perspect

View full text Add to dashboard Cite

show abstract

“…Unfortunately, the efficacy of lifestyle interventions in conjunction with a quit smoking attempt is modest [37]–[39], underscoring the critical need to develop interventions and better diabetes mellitus risk prediction tools to identify smokers that might benefit most from such interventions. A recent systematic review found that combination cessation pharmacotherapies produced less cessation-related weight gain in the short term, but the best results for long-term weight loss involved behavioral interventions [37]. That review did not highlight specific behavioral interventions or predictors of response.…”

Section: Discussionmentioning

confidence: 99%

Smoking Cessation and the Risk of Diabetes Mellitus and Impaired Fasting Glucose: Three-Year Outcomes after a Quit Attempt

et al. 2014

View full text Add to dashboard Cite

Weight gain after smoking cessation may increase diabetes mellitus and impaired fasting glucose (IFG) risk. This study evaluated associations between smoking cessation and continued smoking with incident diabetes and IFG three years after a quit attempt. The 1504 smokers (58% female) were mean (standard deviation) 44.7 (11.1) years old and smoked 21.4 (8.9) cigarettes/day. Of 914 participants with year 3 data, the 238 abstainers had greater weight gain, increase in waist circumference, and increase in fasting glucose levels than the 676 continuing smokers (p≤0.008). In univariate analyses, Year 3 abstinence was associated with incident diabetes (OR = 2.60, 95% CI 1.44–4.67, p = .002; 4.3% absolute excess) and IFG (OR = 2.43, 95% CI 1.74–3.41, p<0.0001; 15.6% absolute excess). In multivariate analyses, incident diabetes was associated independently with older age (p = 0.0002), higher baseline body weight (p = 0.021), weight gain (p = 0.023), baseline smoking rate (p = 0.008), baseline IFG (p<0.0001), and baseline hemoglobin A1C (all p<0.0001). Smoking more at baseline predicted incident diabetes among eventual abstainers (p<0.0001); weighing more at baseline predicted incident diabetes among continuing smokers (p = 0.0004). Quitting smoking is associated with increased diabetes and IFG risk. Independent risk factors include older age, baseline body weight, baseline glycemic status, and heavier pre-quit smoking. These findings may help target smokers for interventions to prevent dysglycemia.Trial RegistrationClinicaltrials.gov NCT00332644

show abstract

“…The prevalence of cigarette smoking in male schizophrenia patients in China is in the range of 54–79% but the prevalence in female schizophrenia patients is remarkably lower at 4–7% (Hou et al, 2011 ; Zhang et al, 2012 ). Notably, a common adverse effect of smoking cessation is weight gain (Yang et al, 2013 ). The average weight gain 6 months after the quit date is between 2.3 and 4.5 kg (Farley et al, 2009 ), which at least partially contributes to the difficulty in quitting smoking, especially in those who are already obese.…”

Section: Introductionmentioning

confidence: 99%

Naltrexone and Bupropion Combination Treatment for Smoking Cessation and Weight Loss in Patients With Schizophrenia

Lyu

Zhan³

et al. 2018

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: The rates of obesity and cigarette smoking are much higher in patients with schizophrenia compared to the general population. This study was to examine whether naltrexone and bupropion combination treatment can help weight loss and smoking cessation in patients with schizophrenia.Methods: Obese male schizophrenia patients with current cigarette smoking were randomized to receive adjunctive naltrexone (25 mg/day) and bupropion (300 mg/day) combination or placebo for 24 weeks. Twenty-two patients were enrolled in the study, and 21 patients completed the study (11 in the treatment group, and 10 in the placebo group). Body weight, body mass index (BMI), fasting lipids, smoking urge, expired carbon monoxide (CO) level and cigarettes smoked per week were measured at baseline and week 24.Results: There was no significant difference between two groups in changes in weight, BMI, fasting lipids, or cigarette smoking measures (p's > 0.05)Conclusion: Naltrexone and bupropion combination treatment didn't show weight loss or smoking cessation effect in patients with schizophrenia in this pilot study.Implications for future studies were discussed.ClinicalTrials.gov identifier: NCT02736474.

show abstract

Does combination pharmacological intervention for smoking cessation prevent post-cessation weight gain? A systemic review

Cited by 14 publications

References 44 publications

Prioritizing Environmental Chemicals for Obesity and Diabetes Outcomes Research: A Screening Approach Using ToxCast™ High-Throughput Data

Prioritizing Environmental Chemicals for Obesity and Diabetes Outcomes Research: A Screening Approach Using ToxCast™ High-Throughput Data

Smoking Cessation and the Risk of Diabetes Mellitus and Impaired Fasting Glucose: Three-Year Outcomes after a Quit Attempt

Naltrexone and Bupropion Combination Treatment for Smoking Cessation and Weight Loss in Patients With Schizophrenia

Contact Info

Product

Resources

About